for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aridis Pharmaceuticals Inc

ARDS.OQ

Latest Trade

6.00USD

Change

-0.02(-0.33%)

Volume

50

Today's Range

6.00

 - 

6.00

52 Week Range

5.51

 - 

12.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.02
Open
6.00
Volume
50
3M AVG Volume
0.22
Today's High
6.00
Today's Low
6.00
52 Week High
12.84
52 Week Low
5.51
Shares Out (MIL)
8.91
Market Cap (MIL)
54.36
Forward P/E
-1.87
Dividend (Yield %)
--

Latest Developments

More

Aridis Pharmaceuticals Says License Agreement With The Serum Institute Of India

Aridis Pharmaceuticals Files For Mixed Shelf Offering Of Up To $100 Mln

Aridis Pharmaceuticals Q2 Loss Per Share $1.03

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.

Industry

Biotechnology & Drugs

Contact Info

5941 Optical Ct

+1.408.3851742

https://aridispharma.com

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-7.450

2019(E)

-3.257
Price To Earnings (TTM)
--
Price To Sales (TTM)
15.83
Price To Book (MRQ)
4.55
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-272.20
Return on Equity (TTM)
-186.39

Latest News

Latest News

Aridis' shares rise in muted market debut

Biotechnology company Aridis Pharmaceuticals Inc <ARDS.O> rose as much as 5.4 percent to $13.70 in its U.S. market debut on Tuesday, joining a host of other small-cap biotechs that have gone public this year.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up